Nama's AI scorecard currently rates Edgewise Therapeutics Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is EWTX's P/E ratio?

Edgewise Therapeutics trades at a trailing price-to-earnings ratio of 5.5.

When does EWTX report earnings?

Edgewise Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.47.

What is the EWTX price target?

The median analyst price target from 12 analysts is $54.00, with a range of $36.00 – $66.00.

Is EWTX Shariah compliant?

Nama's AAOIFI-style screen reads Edgewise Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Edgewise Therapeutics (EWTX)

Healthcare · Biotechnology · NASDAQ

Edgewise Therapeutics (EWTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.93B, a trailing price-to-earnings ratio of 5.5 and a free-cash-flow yield of -3.1%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +131.6% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-7.2%

How far the last close sits under the highest price of the past five years.

Market cap	$4.93B
Trailing P/E	5.5
Price / book	10.8
Price / sales	—
FCF yield	-3.1%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

EWTX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.47). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$9.65	$2.51	+284.5%	$0
Q2 2026	Aug 6, 2026	-$0.53	-$0.47	-12.8%	$0
Q1 2026	May 7, 2026	-$0.46	-$0.48	+4.2%	$0
Q4 2025	Feb 26, 2026	-$0.47	-$0.44	-6.8%	$0

EWTX analyst price target

Median target $54.00 from 12 analysts, ranging $36.00 – $66.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live EWTX data on Nama Insights →

EWTX FAQ

Is EWTX a buy?: Nama's AI scorecard currently rates Edgewise Therapeutics Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is EWTX's P/E ratio?: Edgewise Therapeutics trades at a trailing price-to-earnings ratio of 5.5.
When does EWTX report earnings?: Edgewise Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.47.
What is the EWTX price target?: The median analyst price target from 12 analysts is $54.00, with a range of $36.00 – $66.00.
Is EWTX Shariah compliant?: Nama's AAOIFI-style screen reads Edgewise Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.